Nevro vs Boston Scientific Which Is Stronger?

Nevro and Boston Scientific are both major players in the medical device industry, particularly in the field of neuromodulation. Nevro specializes in innovative spinal cord stimulation technologies, while Boston Scientific offers a wide range of medical devices for various conditions. Both companies have seen growth in recent years, but their stocks have had mixed performance. Investors looking to enter the medical device market may want to consider the differences between Nevro and Boston Scientific before making investment decisions.

Nevro or Boston Scientific?

When comparing Nevro and Boston Scientific, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Nevro and Boston Scientific.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Nevro has a dividend yield of -%, while Boston Scientific has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Nevro reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Boston Scientific reports a 5-year dividend growth of 0.00% year and a payout ratio of 1.29%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Nevro P/E ratio at -2.27 and Boston Scientific's P/E ratio at 74.43. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Nevro P/B ratio is 0.58 while Boston Scientific's P/B ratio is 6.43.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Nevro has seen a 5-year revenue growth of -0.08%, while Boston Scientific's is 0.38%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Nevro's ROE at -24.76% and Boston Scientific's ROE at 8.91%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $4.22 for Nevro and $90.32 for Boston Scientific. Over the past year, Nevro's prices ranged from $3.95 to $22.64, with a yearly change of 473.16%. Boston Scientific's prices fluctuated between $54.95 and $91.93, with a yearly change of 67.30%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.